Liposomal bupivacaine during subcutaneous implantable cardioverter defibrillator implantation for pain management

ConclusionIntraprocedural liposomal bupivacaine administration was not associated with any significant impact on post ‐operative pain scores, inpatient opioid administration, and outpatient opioid prescription rates or OME amounts at discharge.This article is protected by copyright. All rights reserved

Source: Pacing and Clinical Electrophysiology : PACE - January 25, 2021 Category: Cardiology Authors: Justin Z. Lee, Amy E. Glasgow, Elizabeth B. Habermann, Luis Scott, Win ‐Kuang Shen, Fred M. Kusumoto, Christopher J. McLeod, Vasudha Goel, Pranita Kaginele, Yong‐Mei Cha, Paul A. Friedman, Samuel J. Asirvatham, Siva K. Mulpuru Tags: DEVICES Source Type: research